STTK: DR3-targeted therapies show promise for durable efficacy and low immunogenicity in immune diseases
The session highlighted a differentiated approach targeting DR3 for immune diseases, with lower immunogenicity and durable efficacy compared to TL1A antibodies. Phase II trials in Crohn's are underway, with plans to expand into HS and psoriatic arthritis, and a bispecific pipeline advancing.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.